A multidisciplinary approach to optimizing care of patients treated with alpelisib.

ABSTRACT:

Purpose

The oral, α-specific phosphatidylinositol-3-kinase (PI3Kα) inhibitor alpelisib is the first PI3K inhibitor approved for the treatment of advanced breast cancer. As alpelisib is a relatively new therapeutic option, specific guidance and a multidisciplinary approach are needed to provide optimal patient care. The primary objective of this manuscript is to provide comprehensive guidance on minimizing and managing adverse events (AEs) for patients with advanced breast cancer who are receiving alpelisib.

Methods

Clinical studies, prescribing information, published literature, and relevant guidelines were reviewed to provide recommendations on the prevention and management of alpelisib-associated AEs.

Results

The most common AEs associated with alpelisib in the phas

SUBMITTER: Rugo HS 

PROVIDER: S-EPMC8749445 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature